AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02961842 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Ephedrine
Description: Intravenous ephedrine 3, 5, and 10 mg will be administered when Systolic blood pressure decreases below 90%, 80%, and 70% of baseline, respectively.
Study NCT02961842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Ephedrine
Description: Intravenous ephedrine 3, 5, and 10 mg will be administered when Systolic blood pressure decreases below 90%, 80%, and 70% of baseline, respectively.
Study NCT02367560 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Needle decompression
Description: Direct manipulation of calcium deposits in the shoulder with a needle to fragment the deposit performed by a radiologist.
Study NCT02367560 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Shockwave therapy
Description: A physiotherapist performs the shockwave therapy procedure. Treatment is completed in 4 weekly sessions. Treatment involves applying soundwaves directly to the affected shoulder area using an ultrasound device.
Study NCT02367560 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Depo medrol
Description: Subacromial steroid injection (40 mg depo medrol) is given to the patient to limit irritation following needle decompression.
Study NCT02367560 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound device
Description: Ultrasound device is applied directly to the shoulder at 0.2 mJ/mm2.
Study NCT02369653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Study NCT02369653 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No systemic anticoagulant prophylaxis
Study NCT04087447 — intervention group
Intervention type: PROCEDURE
Intervention: Thyroidectomy
Description: Thyroidectomy
Study NCT00666250 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Xocai Activ drink
Description: proprietary blend of cocoa powder and extracts of acai, grape and blueberry
Study NCT02186041 — intervention group
Intervention type: DEVICE
Intervention: Sacral Nerve Modulation
Study NCT03483428 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interventionist training and supervision
Description: Online and in-person training and weekly supervision with licensed clinical social worker while delivering the Family Check-Up to 5 families.
Study NCT03483428 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral parent training
Description: Up to 6 sessions of the Family Check-Up program, involving discussions, assessments, feedback, and skills training with a parent coach.
Study NCT04301050 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga Intervention
Description: Weekly 75-minute yoga classes.
Study NCT00095329 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sirolimus
Study NCT00779337 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous AdE1- Latent Membrane Protein CTLs
Description: Total dose 20-800 million CTL given in 4 equal doses (5-200 million CTL) given intravenously, at weekly intervals for the first cohort of 10 patients and twice a week for the second cohort of 10 patients.
Study NCT04148404 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Normothermic group
Description: 1. Normothermic group (NT group) included patients will undergo CABG under warm bypass using warm blood cardioplegia (Normothermic CBP).~2. Hypothermic group (HT group) included patients will undergo CABG under cold bypass using cold blood cardioplegia (Hypothermic CBP).
Study NCT00896064 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine GSK2189242A (formulation 1)
Description: One dose will be administered intramuscularly at Study Day 0.
Study NCT00896064 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine GSK2189242A (formulation 2)
Description: One dose will be administered intramuscularly at Study Day 0.
Study NCT03345797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Nasal Gel [Natesto]
Description: nasal gel containing 4.5% w/w testosterone
Study NCT02896166 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: microwave ablation
Description: eligible patients will be treated with microwave ablation in the primary tumor sites
Study NCT02025075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: Rocuronium 0.6 - 1.2 mg/kg with the dose adjusted to achieve 1-2 post-tetanic counts (Deep NMB) or 1-2 twitches in the train-on-four (Moderate NMB).
Study NCT02025075 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Description: Rocuronium 0.6 - 1.2 mg/kg with the dose adjusted to achieve 1-2 post-tetanic counts (Deep NMB) or 1-2 twitches in the train-on-four (Moderate NMB).
Study NCT02517723 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Narrative Exposure Therapy
Description: Narrative Exposure Therapy (NET) is based on Testimony Therapy in combination with cognitive behavioural exposure techniques and elements of client-centered counselling. The clients can restore their autobiographic memories about their traumatic experiences. In this way fragmentary memories are transformed into a coherent narrative structure. This practice enables the processing of painful emotions and the construction of clear contingencies of dangerous and safe conditions, generally leading to significant emotional recovery. Therapeutic aims are the reduction of PTSD-Symptomload via activation of fear-network and habituation of fear and the placement of traumatic experiences in a reconstructed, detailed and consistent autobiography.~NET will be applied in eight sessions (90-120min/session) in a standardized, manualized manner.
Study NCT02517723 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dialectical Behavior Therapy
Description: Dialectical behavior therapy is a cognitive behavioral treatment program developed by Marsha Linehan to treat suicidal clients meeting criteria for BPD. It directly targets suicidal behavior, behaviors that interfere with treatment delivery, and other dangerous, severe, or destabilizing behaviors.~Via standard DBT patients improve behavioral capabilities, motivation for skillful behavior, generalization of gains to the natural environment, structuring the treatment environment so that it reinforces functional rather than dysfunctional behaviors. It also targets the therapist capabilities and motivation to treat patients effectively. Patients get weekly individual psychotherapy (1 h/wk), group skills training (3.75 h/wk), a weekly therapist consultation team meetings.
Study NCT02517723 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Inpatient Care
Description: Unspecific group therapy that is identical in both groups (music therapy etc.)
Study NCT02517723 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Inpatient Care
Description: Unspecific group therapy that is identical in both groups (music therapy etc.)
Study NCT02517723 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Waiting List
Description: Treatment as usual in the community (no DBT, no exposure of trauma memories)
Study NCT02517723 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Waiting List
Description: Treatment as usual in the community (no DBT, no exposure of trauma memories)
Study NCT00383526 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated, split-virion influenza vaccine
Description: Vaccine
Study NCT00383526 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated, split-virion influenza vaccine
Description: Vaccine
Study NCT01653691 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulse-Dye Laser
Description: Laser therapy will be applied to either one half or both halves of the subject's burn scar. Laser will be re-applied every 4-6 weeks for a total of 3 administrations.
Study NCT01653691 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: No treatment to one side of subject's scar.
Study NCT02999685 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home-base Pulmonary Rehab with Health Coaching
Study NCT04666623 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: esketamine nasal spray
Description: unlabeled nasal injectors, each device will deliver 28mg of esketamine in a 200 μL solution, so in order to achieve the 56mg dose two devices will be required. On each dosing day during the trial, participants will self-administer at 2 time points 1 spray of the nasal spray into each nostril. Each administration will be separated by 5 minutes. The participants will receive the intervention twice weekly for 4 consecutive weeks.
Study NCT04666623 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo nasal spray
Description: unlabeled nasal injectors, each device will deliver 28mg of placebo in a 200 μL solution, so in order to achieve the 56mg dose two devices will be required. On each dosing day during the trial, participants will self-administer at 2 time points 1 spray of the nasal spray into each nostril. Each administration will be separated by 5 minutes. The participants will receive the intervention twice weekly for 4 consecutive weeks.
Study NCT01620268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leflunomide and orotic acid
Description: Daily dose of leflunomide adjusted to target steady state blood levels of 50 ug/mL to 100 ug/mL of the active metabolite plus 600 mg orotic acid
Study NCT04662333 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transcrestal approach for sinus lift
Description: After surgical exposure of maxillary alveolar crest, implant site preparation and transcrestal detachment of Schneiderian's membrane will be performed. Thereafter implant will be placed, protruding in the maxillary sinus with its apical part.
Study NCT04662333 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcrestal approach for sinus lift
Description: After surgical exposure of maxillary alveolar crest, implant site preparation and transcrestal detachment of Schneiderian's membrane will be performed. Thereafter implant will be placed, protruding in the maxillary sinus with its apical part.
Study NCT04662333 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Xenograft application
Description: Before implant placement, xenogenic collagen membrane and bone granules will be pushed under the Schneiderian's membrane through the surgical site.
Study NCT03189082 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microbotox
Description: Microbotox is the injection of multiple microdroplets of diluted botulinum toxin into the dermis of the lower face
Study NCT00083915 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 20mg/m2 continuous infusion days -3 and -2.
Study NCT01901432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Givinostat
Description: In Part A patients will treated in dose levels at the following daily doses of Givinostat:~* 50 mg b.i.d.,~* 100 mg b.i.d.;~* 150 mg b.i.d.,~* 200 mg b.i.d.;~* 150 mg t.i.d.;~* 200 mg t.i.d.. Intermediate dose levels and, consequently, additionally dose levels may be used to establish the Maximum Tolerated Dose.~In Part B patients will be treated at the Maximum Tolerated Dose established in Part A. The product will be supplied as hard gelatine capsules for oral administration at the strength of 50 mg, 75 mg and/or 100 mg each.
Study NCT04579718 — intervention group
Intervention type: OTHER
Intervention: Zeus Cloud TPS V1.0
Description: Zeus Cloud TPS V1.0 is used to design the radiotherapy plan for the subjects and the plan is evaluated.
Study NCT04579718 — intervention group
Intervention type: OTHER
Intervention: Eclipse
Description: Eclipse TPS of Varian company is used to design the radiotherapy plan for the subjects and the plan is evaluated.
Study NCT00083915 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 800 mg/m2 continuous infusion days -3 and -2.
Study NCT00083915 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adriamycin
Description: 20mg/m2 continuous infusion -3 and -2.
Study NCT00083915 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: 80mg/m2 continuous infusion -3 and -2.
Study NCT00083915 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan
Description: 200 mg/m2 IV over \<20 minutes on -1 on Arm 1. 50mg/m2 IV over 20 minutes days -3 and -2 on Arm 2.
Study NCT00083915 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thalidomide
Description: 200mg PO Continuing to Day +5, then hold until platelets >50 thousand (K).
Study NCT00083915 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 40 mg po days 1 - 4 (4 days)
Study NCT01276977 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zolmitriptan 5 mg Nasal Spray
Description: Patients will treat 2 migraine attacks with zolmitriptan 5 mg nasal spray and 2 migraine attacks with eletriptan.
Study NCT01276977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolmitriptan 5 mg Nasal Spray
Description: Patients will treat 2 migraine attacks with zolmitriptan 5 mg nasal spray and 2 migraine attacks with eletriptan.
Study NCT01276977 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eletriptan 40 mg tablet
Description: Patients will treat 2 migraine attacks with Eletriptan and 2 migraine attacks with zolmitriptan 5 mg nasal spray
Study NCT01276977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eletriptan 40 mg tablet
Description: Patients will treat 2 migraine attacks with Eletriptan and 2 migraine attacks with zolmitriptan 5 mg nasal spray
Study NCT03913962 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: indirect calorimetry
Description: Patients will be separated in different subgroups. Subgroups will be constituted according the disease status (i.e. active vs inactive) to assess the impact of the pathology on physical fitness and according to treatments to assess the effect of treatment on physical fitness.
Study NCT03913962 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: indirect calorimetry
Description: Patients will be separated in different subgroups. Subgroups will be constituted according the disease status (i.e. active vs inactive) to assess the impact of the pathology on physical fitness and according to treatments to assess the effect of treatment on physical fitness.
Study NCT00551369 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: SBRT delivered in 3 fractions of 20 Gy/fraction over 1.5 to 2 weeks for a total of 60 Gy
Study NCT01066234 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: concurrent chemoradiotherapy
Description: weekly paclitaxel 50mg/m2 plus weekly cisplatin 25mg/m2 5times with concurrent radiotherapy (5000rad/25fx) for 5 weeks followed by 2 cycles of 3-weekly paclitaxel (175mg/m2) plus cisplatin 80mg/m2.
Study NCT01066234 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy only
Description: four cycles of 3-weekly paclitaxel (175mg/m2) and carboplatin (AUC5.5).
Study NCT02675166 — intervention group
Intervention type: OTHER
Intervention: Pediatric cancer young adult survivors
Description: Patients will receive a questionnaire, a consultation with an oncologist and a psychologist will be planned, and two years later, patients will have to answer again to the questionnaire.
Study NCT00912366 — intervention group
Intervention type: PROCEDURE
Intervention: Lobectomy
Description: Assessment of VATS versus open surgery.
Study NCT03287544 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined rehabilitation
Description: Linguistic training as well as communication training.
Study NCT03287544 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Linguistic rehabilitation
Description: Rehabilitation only focused on linguistic processes.
Study NCT00834184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nikkomycin Z
Description: Multiple rising doses. Doses packaged on a unit dose basis in 250 mg capsules. Subjects take 1-3 capsules per dosing block for 14 days unless ADE or study withdrawal. Dose escalation unless a dose-limiting adverse effect is noted. Subjects assigned to BID dosing will receive 28 doses and subjects assigned to TID dosing will receive 42 doses.~250 mg BID (n=6) vs Placebo capsule BID (n=2), 500 mg BID (n=6) vs Placebo capsule BID (n=2), 750 mg BID (n=6) vs Placebo capsule BID (n=2), 750 mg TID (n=6) vs Placebo capsule TID (n=2) At least 4 subjects complete lower dose before randomization includes next higher dose, thus there are 4 arms for active intervention and corresponding placebos.
Study NCT01241487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valsartan/amlodipine
Description: 160/10 mg
Study NCT02333305 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CoQ10
Description: • 2 dosages according to patient weight: Weight \< 50kg : 20 drops 3 times a day (150 mg / d) Weight ≥ 50 kg : 40 drops 3 times a day (300 mg / d)
Study NCT02333305 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sanomit Placebo
Description: • according to patient weight: Weight \< 50kg : 20 drops 3 times a day Weight ≥ 50 kg : 40 drops 3 times a day
Study NCT01192464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: autologous CAR.CD30 EBV specific-CTLs
Description: Three dose levels will be evaluated. Using the modified continual reassessment method, cohorts of size two will be enrolled at each dose level. Each patient will receive one injection.
Study NCT03360734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: First part: Gatipotuzumab and Tomuzotuximab; Second part: Gatipotuzumab and Tomuzotuximab or anti-EGFR antibody (Cetuximab, Panitumumab or Necitumumab)
Description: Two monoclonal antibodies, Gatipotuzumab is anti-TAMUC1, Tomuzotuximab is anti-EGFR
Study NCT01790399 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Excision of sentinel node(s)
Description: Excision of sentinel node(s) using SENTIMAG / SIENNA + in addition to the usual method (blue and /or radioactive product)
Study NCT00719901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: obatoclax mesylate
Description: Given IV
Study NCT00719901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV
Study NCT00719901 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03953716 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low level light therapy
Description: Start using low level light therapy after the menstrual period, once a day, every 20 minutes \* 5 days ( one treatment cycle), start the next course at intervals of 2 days until the next menstruation
Study NCT03953716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DING KUN DAN
Description: DING KUN DAN,3.5g BID for 10 days (starting 3-5 days before menstruation) \*3 menstrual cycle
Study NCT03953716 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Simulated drug of DING KUN DAN
Description: Simulated drug of DING KUN DAN，3.5g BID for 10 days (starting 3-5 days before menstruation) \*3 menstrual cycle
Study NCT03953716 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marvelon
Description: Marvelon 1 pill QD\*21 days (starting on the 5th day of menstruation, continuing the next cycle after 1 week of withdrawal) \*3 menstrual cycle
Study NCT04716777 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Transdiagnostic group-based Cognitive-Behavioral Treatment
Description: Weekly group-based transdiagnostic CBT sessions for eight weeks.
Study NCT02349386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BHR-200 (0.36% transdermal 17β-estradiol gel)
Description: An absorptive hydroalcoholic gel preparation containing 17β-estradiol.
Study NCT02349386 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An absorptive hydroalcoholic gel preparation gel of the same ingredients as BHR-200, but without 17β-estradiol.
Study NCT01847677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Study NCT01847677 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Study NCT02033798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Description: Once Daily 0.2mg per oral for 6 months
Study NCT00091819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telavancin
Description: Telavancin 10 mg/kg/day, IV for up to 14 days.
Study NCT01847677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study NCT01847677 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Study NCT01847677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study NCT02952118 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Forrest Snoring device
Study NCT04695522 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ADR-002K administration
Description: ADR-002K administration
Study NCT04695522 — intervention group
Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: ADR-002K administration
Description: ADR-002K administration
Study NCT03561662 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Alpro soya drinks
Description: 12 weeks
Study NCT02243111 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Doppler ultrasound
Description: Detecting Doppler signals from the lungs on the right chest wall